Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

Related Keywords

Boston ,Massachusetts ,United States ,Mark Manfredi ,Jotin Marango ,Rebecca Cohen ,Mike Tattory ,Exchange Commission ,Ikena Oncology Inc ,Nasdaq ,Chief Executive Officer ,Selective Hippo Pathway ,Chief Financial ,Private Securities Litigation Reform Act ,Quarterly Report ,